* All times are based on Canada/Eastern EST.
07:30
Canada/Eastern
08:30
Canada/Eastern
10:00
Canada/Eastern
New functions of delta opioid receptors in pain and reward circuits
Chairs: Marie Walicki, Graduate student, University of Michigan; Emily Jutkiewicz, Associate Professor, University of Michigan Speakers: William Birdsong, Assistant Professor, University of Michigan. Adaptations in delta opioid receptor function in the anterior cingulate cortex Élora Midavaine, Postdoctoral Fellow, UCSF. Meningeal regulatory T cells gate nociception through an endogenous opioid circuit Elizaveta Mangutov, Graduate Student, Washington Univ St. Louis. Delta opioid receptor activation blocks allodynia in a model of PACAP-induced headache Emily Jutkiewicz, Associate Professor, University of Michigan. (Re)Evaluating the reinforcing effects of delta-opioid receptor agonists
11:30
Canada/Eastern
Hot Topics
Chair: John Traynor, Professor, University of Michigan Speakers: Tao Che, Assistant Professor, Washington University St. Louis. The functional diversity of G proteins in opioid receptor signaling Merel Dagher, Postdoctoral Fellow, UCLA. Inhibition of CeA-dynorphin neurons is reinforcing in mice with chronic pain Viktor Yarotskyy, Assistant Professor, Virginia Commonwealth University. Fentanyl inhibits neuronal activity in dissociated striatal medium spiny neurons co-cultured with glia through a non-opioid receptor dependent mechanism
12:00
Canada/Eastern
Lunch and Learn with the University of Michigan Opioid Research Institute
The Current Landscape of Opioid Addiction Treatment and Prescribing of Opioid-Related Medications in the U.S. Chairs: Amy Bohnert, PhD, MHS, Professor and Co-Director, ORI; Chad Brummett, MD, Professor, Co-Director, ORI Speakers: Pooja Lagisetty, MD - Title: Current Treatment Practices and Access Considerations for OUD Kao-Ping Chua, MD, PhD - Title: U.S. trends in dispensing of prescription opioids, buprenorphine, and naloxone Lunch is provided!
14:00
Canada/Eastern
Translational advances of nociceptin opioid receptor (NOP) ligands in SUD and other psychiatric diseases
Chairs: Nurulain T. Zaveri, President and Chief Scientific Officer, Astra Therapeutics; Larry Toll, Professor, Florida Atlantic University Speakers: Valentine Pascale, Imbrium Therapeutics - Title: Development of a selective NOP partial agonist, Sunobinop, with sleep promoting effects and utility for substance use disorders including alcohol use disorders Joseph Greico, Tris Pharma - Title: Clinical data of cebranopadol, the NOP-MOP agonist, for pain and OUD Larry Toll, Professor, FAU. PPL-138, non-addicting analgesic and more